[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"myelosuppression-adult\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:myelosuppression-adult":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100567249","phase-4-outcomes-of-early-and-late-administration-g-csf-for-primary-prophylaxis-in-non-hodgkins-lymphoma-patients-100567249",false,"NCT06665737","Outcomes of Early and Late Administration G-CSF for Primary Prophylaxis in Non-Hodgkin's Lymphoma Patients","A Comparison Outcomes of Early and Late Administration G-CSF for Primary Prophylaxis in Non-Hodgkin's Lymphoma Patients Who Receive Chemotherapy, Multicenter Study","G-CSF in NHL","Inclusion Criteria:\n\n* Aged 18 years or old\n* Confirmed lymphoma undergoing standard chemotherapy\n* Signed an approval informed consent\n* Has a good understanding of Thai\n* Available for follow-up after chemotherapy\n\nExclusion Criteria:\n\n* Pregnancy or lactation\n* Serious concomitant diseases and discontinuous treatment such as cardiovascular, liver, or kidney diseases\n* Contraindication to chemotherapy or G-CSF administration\n* Antibiotic use within 1 week prior to enrollment","ALL","18 Years",{"count":20,"type":21},126,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The goal of this clinical trial is to\n\nPrimary Objectives:\n\n1. To compare the incidence of febrile neutropenia in patients with non-Hodgkin's lymphoma who received early or late granulocyte colony-stimulating factor (G-CSF) during standard chemotherapy in a multicenter study\n2. To determine the incidence of leukopenia and neutropenia in patients with non-Hodgkin's lymphoma who received early or late G-CSF during standard chemotherapy in a multicenter study\n\nSecondary Objectives:\n\n1. To determine changes in white blood cell, hemoglobin, and platelet levels in patients with non-Hodgkin's lymphoma who received early or late G-CSF during standard chemotherapy.\n2. To determine the quality of life of patients with non-Hodgkin's lymphoma who undergoing standard chemotherapy and with neutropenia Researchers will compare the outcome between patients received either early G-CSF (within 72 hours) or late G-CSF (after 72 hours).\n\nAll patients will be followed up to monitor for febrile neutropenia events, other hematological parameters and quality of life.",[27,28,29,30],"Non-Hodgkin's Lymphoma (NHL)","Granulocyte Colony Stimulating Factor","Febrile Neutropenia (FN)","Myelosuppression Adult",[32,33,28,34],"Non-Hodgkin's lymphoma","Febrile neutropenia","Myelosuppression","NOT_YET_RECRUITING","2025-01-24",{"date":38,"type":39},"2025-01-28","ACTUAL",{"date":41,"type":21},"2025-02-01",{"date":43,"type":21},"2026-12-31",{"name":45,"class":46},"Department of Medical Services Ministry of Public Health of Thailand","OTHER_GOV",3]